Slides
Page 1
Proteomics International LABORATORIES LTD Investor Presentation: Commercial Launch Bell Potter Healthcare Conference 18-20 November 2025 Dr. Richard Lipscombe Managing Director For personal use only
Page 2
2 ASX: PIQ Forward Looking Statements This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company. The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct. No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived. Material Business Risks. The Company has identified specific risks that could impact upon its future prospects. These risks are listed in the PIQ 2025 Annual Report. For personal use only
Page 3
3 ASX: PIQ Launching four first-in-class diagnostics in 2025 Proteomics International Key Highlights Large addressable markets with significant unmet medical needs Tests validated in large clinical studies Significant advantages over current Standards-of-Care Consumer driven strategy • Targeting Primary Care & GP Clinics • Patient digital platform built • Proven demand with KOLs on board Products developed Patented Highly attractive margins Funded to execute launch strategies Strategically positioned to secure Licencing Agreements OxiDx For personal use only
Page 4
ASX: PIQ 4 • A novel and accurate blood test for predicting the onset of chronic kidney disease in type 2 and type 1 diabetes (DKD) • Currently 1 in 2 people with diabetes will develop DKD • DKD leads to dialysis/kidney transplant; US reimbursement price pending • Ramp-up phase following launch in Australia and USA in Q2 and Q3 CY25 • First-in-class blood test identifies all stages of endometriosis with high accuracy • Current diagnosis takes average 7 yrs and requires invasive laparoscopy • Launch in Australia in CY25 pending; USA to follow • A novel and accurate blood test to diagnose esophageal cancer • Commonly caused by chronic acid reflux (or ‘GERD’) • Current diagnosis requires endoscopy + biopsy • Ramp-up phase following launch in Australia in Q3 CY25; USA pending • Unique test precisely identifies muscle damage & assesses training recovery • In professional sports muscle damage accounts for 55% of injuries, while 85% of racehorses get injured during their 2- & 3- year-old racing seasons • Launch in Australia in CY25 pending; USA to follow Targeting major diseases which are currently detected late → existing outcomes are poor for patients & cost healthcare system billions of dollars Problem & Solution: a suite of novel diagnostic tests International Diabetes Federation (IDF) Endometriosis, World Health Organisation (WHO.org) Country specific use of these products is subject to the relevant regulatory approvals For personal use only
Page 5
ASX: PIQ 5 Drive near-term revenue with maximum optionality for strategic partnering 5 ✓ Developed suite of highly accurate, tests for large unmet medical needs ✓ Platform, analytical infrastructure & digital sales pathway built ✓ Enables tech transfers of each clinical test to future partners ✓ Provides fastest pathway to achieving product launch and revenues ✓ Reimbursement pricing (USA) imminent for PromarkerD – other tests to follow ✓ Engagement with GP clinics, KOLs & end users to refine sales practices ✓ Grow market awareness via traditional and digital avenues • Increase market up-take as market awareness improves ✓ Attractive pre-built platform for any potential licensing partner: o Global virtual health and diagnostic companies • Leverage more attractive terms for out-licensing as tests are in market Focus on market awareness and launch of tests Grow sales via strategic partnershipsDemonstrate market adoption and sales • Industry and Governments are focusing on Personalised/Precision medicine • Healthcare and diagnostic companies actively seeking new diagnostic tests • Ongoing dialogue with prospective strategic partners • Company will retain optionality for its tests: o Drive revenue through the platform o Non-exclusive licensing agreements & retain use of platform o Provide exclusive rights to licensing partners Market Launch: Ramp Up → Partnering For personal use only
Page 6
ASX: PIQ 6 Milestones: multiple value drivers achieved & ahead Milestone TARGET QTR FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Impact Commercial Australian clinical lab established Basis for all Promarker tests to be run clinically US reference lab established Key to first US sales and reimbursement PromarkerD launched in W. Australia Pilot launch to optimise logistics & digital framework PromarkerD launched across Australia Enable clinical testing in Australia and tech transfer overseas PromarkerD launched in USA Initiate pathway to significant revenues PromarkerEso launched in Aus/USA Initiate pathway to significant revenues PromarkerEndo launched in Aus/USA Initiate pathway to significant revenues Material sales of PromarkerD Drive future revenue Promarker tests licensing deals Drive regional uptake and future revenue Clinical/Technical Promarker tests validation studies New first-in-class diagnostic tests Promarker diagnostics pipeline updates New diagnostic tests in development Reimbursement PromarkerD reimbursement code granted Support US roll-out PromarkerD PLA code pricing set Broaden usage of test in USA PromarkerEso PLA code application Support US roll-out ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ For personal use only
Page 7
7 ASX: PIQ • Commercialising x4 first-in-class blood tests for major diseases and conditions with significant unmet need • Ramp-up phase for PromarkerD & PromarkerEso with first sales already achieved • Commercial platform developed to drive awareness for each test in Australia and USA to attract strategic partners • Proprietary platform technology provides engine to develop further tests • Funding, team, infrastructure and certifications in place • Catalyst rich Financial Year 2026 Investment Summary For personal use only
Page 8
ASX: PIQ 8 Contact ASX:PIQ Dr Richard Lipscombe Managing Director T: +61 8 9389 1992 E: enquiries@proteomicsinternational.com www.proteomicsinternational.com For personal use only